SUSTAINED RELEASE MATRIX TABLETS OF DICLOFENAC SODIUM EMPLOYING KOLLIDON SR, PEG 6000, LACTOSE MONO HYDRATE AND EUDRAGIT S100 IN COLON TARGET

Matrix Tablets, each containing 50 mg of diclofenac sodium, are prepared employing Kollidon SR by direct compression method. All the tablets were found to be non-disintegrating in acidic (pH1.2) and alkaline (pH 7.4) fluids. As such, the prepared tablets were of good quality with respect to drug content, hardness and friability. As the tablets formulated were non- disintegrating in acidic fluids, they are considered suitable for colon targeting. From the drug release study, it may be concluded that the (DK2) E2 formula of diclofenac sodium matrix tablets gives the desired release profile by showing a minimal release during the lag period of 5 h and complete release at the end of 12 h. The tablets having the optimised formula (DK2)E2, having 25% Kollidon SR with 5% of channelling agent (Eudragit S100 to that of Kollidon SR) showed minimal release of 27. 4% in the lag period of 5 hours and 99.3 % of the drug was released y the end of 12 h. The diclofenac sodium matrix tablets formulated by employing Kollidon SR and various channelling agents showed non-Fickian diffusion mechanism and followed zero order kinetics. The optimized formula (DK2) E2 follows Supercase II transport as mechanism for drug release and it follows zero order kinetics. Matrix tablets (DK2) E2 formulated employing 25% Kollidon SR and 5% Eudragit S100 are best suited to be used for colon targeting of diclofenac sodium.